Prothena Corporation plc
NASDAQ: PRTA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Nasdaq Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Gene Kinney
- Employees
- 67
- Headquarters
- Dublin, Ireland
- IPO year
- 2012
- Market cap
- $492.1M
- Website
- https://www.prothena.com
Loading PRTA…
Loading profile data…Frequently asked questions about PRTA
What does Prothena Corporation plc (PRTA) do?
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson’s disease...
Where does PRTA trade?
Prothena Corporation plc (PRTA) trades on the Nasdaq Global Select.
What sector is PRTA in?
Prothena Corporation plc (PRTA) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Prothena Corporation plc?
Gene Kinney is the chief executive officer of Prothena Corporation plc (PRTA).
Where is Prothena Corporation plc headquartered?
Prothena Corporation plc is headquartered in Ireland.
Does PRTA pay a dividend?
Prothena Corporation plc (PRTA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did PRTA go public?
Prothena Corporation plc (PRTA) completed its initial public offering in 2012.